ASX ANNOUNCEMENT

Strategic Update and Teleconference Call Notification

Sydney, 21 April 2021. Actinogen Medical ASX: ACW ('ACW' or 'the Company') is pleased to provide a strategic update and release a corporate investor presentation. Actinogen's Chief Executive Officer and Managing Director, Dr Steven Gourlay, will be hosting a teleconference on Friday, 23 April 2021 at 9.00am AEST. This teleconference will be used to update existing shareholders, potential investors and other strategic parties on Actinogen's clinical development pipeline, commercial strategy and outlook going forward.

Key highlights:

- **Xanamem™ is a brain penetrant 11β-HSD1 small molecule enzyme inhibitor, that works to inhibit excess cortisol production inside brain cells**
- **Review of data completed to optimise clinical trial planning, with Phase I data highlighting modern and sensitive, computerised measurement tools and PET brain scan data supporting efficacy of Xanamem in doses as low as 5mg**
- **XanaMIA Phase II trial to commence in CY21 and to be executed in two parts;**
  - Part A: Dose ranging study seeking to confirm minimum effective Xanamem dose
  - Part B: Investigating efficacy of Xanamem in patients with mild cognitive impairment due to Alzheimer's disease, bridging positive Phase I data (healthy older subjects and PET brain scan data) to an early stage Alzheimer's population
- **XanaFX Phase II trial in adolescents with Fragile X syndrome is fully funded, with strategic benefits from Rare Paediatric Disease Designation awarded by the FDA supporting clinical development and a pre-IND interaction with the FDA pending**
- **Strong cash balance of ~$15.23m as 31 March 2021, with XanaMIA and XanaFX fully funded**
- **Dr Steven Gourlay to deliver presentation on a Teleconference at 9:00am on Friday, 23 April 2021**

Dr Steven Gourlay, Actinogen CEO and MD, commented:
"After many years of working in the biopharma industry, I am excited by the huge potential of Actinogen. In my last major role at Principia Biopharma as Chief Medical Officer, I steered two small molecules from a microcap company valuation, through successful Phase II development and into Phase III, resulting in a significant value appreciation for shareholders when the company was acquired for US$3.7B. I find Actinogen to be a similar investment opportunity: excellent science, a promising Phase II molecule for multiple indications, with an attractive valuation, and so accepted the role as CEO / MD, and personally invested over A$300K into the Company prior to my appointment.

We are now planning for multiple shots on goal and strongly believe the upcoming trials are designed to achieve informative and positive outcomes. I look forward to working with the team to further develop Xanamem as we progress the development pipeline."

Alzheimer's disease remains a focus for Actinogen, with the XanaMIA trial expected to commence this year. This trial is designed to leverage the positive Phase I cognition data in healthy elderly subjects to bridge the gap to an early Alzheimer's population, with the potential to limit further impairments as Alzheimer's progresses. XanaMIA is planned to utilise the sensitive Cogstate Neurological Test Battery ("Cogstate"), a

computerised test battery measuring a range of cognitive capabilities which was used in the Phase I trial, including the Digit Symbol Substitution Test or iDSST. The iDSST has been recognised in the past by the FDA as an approvable endpoint for a cognitive marketing claim. The PET human brain scan data generated in Actinogen's Target Occupancy study supports daily doses as low as 5mg.

XanaMIA Part A is a dose ranging study designed to confirm the minimum effective dose of Xanamem before moving into larger trials. The study will assess healthy elderly patients at 5mg, 10mg and placebo. The results will be used to inform XanaMIA Part B, which will investigate the efficacy of Xanamem in patients with mild cognitive impairment (MCI) due to Alzheimer's disease. The trial has been designed to utilise serum biomarkers to positively identify MCI as related to Alzheimer's, and dementia assessment scales to ensure patients are early stage, and do not have the functional impairment present in later stage Alzheimer's. Part B endpoints will also include Cogstate and iDSST, as well as other endpoints previously accepted by regulators.

Plans for the XanaFX Phase II trial targeting adolescents with Fragile X syndrome (FXS) are advancing, with a FDA Pre-IND interaction expected in mid CY21 which will inform trial commencement, currently expected in CY21. Actinogen was recently awarded Rare Paediatric Disease Designation in FXS which includes priority review and potentially faster clinical development and commercialisation of Xanamem in FXS, as well as a separate, tradeable priority review voucher.

Actinogen continues to focus on various shareholder value drivers through a strong commercialisation strategy, including multiple trials in clinical development and a focus on business development activities. As part of this, Actinogen continues to assess additional opportunities to expand the clinical pipeline beyond Alzheimer's and FXS.

Actinogen's presentation is attached to this announcement.

Teleconference Notification

Conference call details:
Date: Friday, 23 April 2021
Time: 9.00am (AEST)

Registration details
Participants are encouraged to pre-register for the webcast through the link below. Upon registration, participants will receive a unique pin granting fast-track access to the conference call.
https://s1.c-conf.com/diamondpass/10013510-v1ru5s.html

If you do not pre-register for the event, you can dial into the event using one of the numbers below. Please dial in five minutes before the webcast begins and provide your name and the participant PIN code.

Participant PIN code: 10013510

Dial-in numbers:

Australia:	1800 455 963	**USA/Canada:**	1 855 624 0077
New Zealand:	0800 452 795	**UK:**	0800 051 1453
Singapore:	800 101 2702	**Spain:**	900 823 322
Hong Kong:	800 968 273	**Switzerland:**	0800 802 498
Malaysia:	1800 816 441	**Other International:**	+61 7 3145 4005

A transcript of the conference call will be made available on the ASX in the days following the call.

ENDS

Actinogen Medical **Investor Enquiries**

Dr. Steven Gourlay
CEO & Managing Director
P: +61 2 8964 7401
E: steven.gourlay@actinogen.com.au

Miranda Newnham
Vesparum Capital
P: +61 3 8582 4800
E: actinogen@vesparum.com

Announcement authorised by the Board of Directors of Actinogen Medical

About Actinogen Medical

Actinogen Medical (ASX:ACW) is an ASX-listed biotechnology company developing novel therapies for neurological diseases associated with dysregulated brain cortisol. The company is currently developing its lead compound, Xanamem™, as a promising new therapy for Alzheimer's Disease, Fragile X syndrome, and other potential neurological diseases. The cognitive dysfunction, behavioural abnormalities, and neuropsychological burden associated with these conditions is significantly debilitating for patients, and there is a substantial unmet medical need for new and improved treatments.

About Xanamem™

Xanamem's novel mechanism of action works by blocking the production of intracellular cortisol – the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. There is a strong association between persistent stress and the production of excess cortisol that leads to detrimental changes in the brain, affecting memory, cognitive function and behaviour and neuropsychological symptoms.

The Company has studied 11β-HSD1 inhibition by Xanamem in more than 200 volunteers and patients, finding a statistically significant improvement in cognition over placebo in healthy, older volunteers. A series of Phase II studies in multiple indications will be conducted to further confirm and characterise Xanamem's efficacy and safety.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority. Xanamem™ is a trademark of Actinogen Medical.

Disclaimer

This announcement and attachments may contain certain forward-looking statements that are based on subjective estimates and assumptions and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements involve known and unknown risks, uncertainties, and other factors (such as significant business, economic and competitive uncertainties and contingencies, and regulatory and clinical development risks and uncertainties) which may cause the actual results or the performance of Actinogen Medical to be materially different from the results or performance expressed or implied by such forward looking statements. Past performance is not a reliable indicator of future performance. There can be no assurance that any forward-looking statements will be realised. Actinogen Medical does not make any representation or give any warranty as to the likelihood of achievement or reasonableness of any forward-looking statements.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.



Strategic Update & Investor Presentation

Dr. Steven Gourlay: CEO & MD

April 2021

After many years of working in the biopharma industry, I am excited by the huge potential of Actinogen.

In my last major role at Principia Biopharma as Chief Medical Officer, I steered two small molecules from a microcap company valuation, through successful Phase II development and into Phase III, resulting in a significant value appreciation for shareholders when the company was acquired for US$3.7B.

I find Actinogen to be a similar investment opportunity: excellent science, a promising Phase II molecule for multiple indications, with an attractive valuation, and so accepted the role as CEO / MD and personally invested over A$300K into the company prior to my appointment.

We are now planning for multiple shots on goal and strongly believe the upcoming trials are designed to achieve informative and positive outcomes. I look forward to working with the team to further develop Xanamem as we progress the development pipeline.

- Dr Steven Gourlay, Actinogen CEO / MD

Executive summary

Actinogen Medical (ASX:ACW) is developing a novel treatment to address significant unmet need in a range of central nervous system (CNS) diseases with **rapid onset of clinical activity demonstrated**

Drug well understood	▪ Xanamem demonstrated to be a brain penetrant 11β-HSD1 small molecule enzyme inhibitor, that works to safely inhibit excess cortisol production in the brain ▪ Favourable drug attributes (e.g. low daily dose, rapid effect, co-administrable, safe) and can be leveraged across multiple indications
Significant dataset leveraged into clinical pathway	▪ Phase 1 study demonstrated statistically significant efficacy signals in multiple cognition domains in healthy patients using a modern and sensitive endpoint, which can now be utilised in future studies ▪ Human Target Occupancy Study PET data demonstrates consistent suppression of enzyme activity in the brain across a range of doses ("flat dose-response curve") - supporting a low dose of Xanamem
Advancing multiple near-term clinical trials	▪ Seeking to confirm minimum effective Xanamem dose (XanaMIA Part A), to inform XanaMIA Part B in patients with Mild Cognitive Impairment due to Alzheimer's disease ▪ Phase II trial in patients with Fragile X syndrome (XanaFX), with Rare Paediatric Disease Designation awarded by US FDA
Strong outlook with significant value upside	▪ Strong cash balance of ~$15.2M[1], with planned clinical trials fully funded ▪ Clinical trials to commence in CY21, with Actinogen assessing additional indications ▪ Targeting value creating opportunities by proactively engaging with potential future partners

Actinogen Medical

FDA: Food and Drug Administration (US)
1. Cash balance as at 31 March 2021

Xanamem™ – small molecule drug with a novel mechanism of action

Xanamem is a brain[1] penetrant 11ß-HSD1 small molecule enzyme inhibitor; designed to inhibit excessive cortisol production in the brain



1. Xanamem is a CNS (Central Nervous System) penetrant small molecule

Xanamem™ - favourable profile across multiple domains

Further clinical development of Xanamem underpinned by attractive characteristics

- ✓ **Rapid clinical effect:** Improved attention and working memory seen as early as 2 weeks after first treatment[1]; hormone pharmacodynamic activity maximal at 10mg dose, with high brain PET occupancy at 7 days
- ✓ **Low dose, daily:** Demonstrates high bioavailability with slow clearance supporting low-dose, once daily administration, providing potential compliance and commercial benefits
- ✓ **Brain penetrant:** Effective levels of Xanamem measured in the brain, consistent with human brain PET pharmacodynamic activity shown at doses ≥5mg
- ✓ **Co-administrable:** Low drug to drug interaction potential; other medications able to be used concurrently with Xanamem
- ✓ **Safety database >200 subjects:** Safety profile demonstrated in multiple human trials

Xanamem is a platform drug and can be leveraged across multiple indications

Actinogen Medical

CNS (Central Nervous System)
1. Demonstrated in Phase 1 XanaHES clinical trial

Key achievements place Actinogen in a strong position going forward

- ✓ **Xanamem demonstrates cognitive[1] activity and pharmacodynamic activity (11ß-HSD1 inhibition)** in preclinical and clinical trials, underpinned by a substantial clinical safety database
- ✓ **Xanamem manufacturing process and supply chain optimised** to improve commercial viability, and time required for manufacturing
- ✓ **US FDA[2] granted Rare Paediatric Disease Designation** for Fragile X syndrome
- ✓ **Well funded,** with ~$15M capital raised in 2020/21 to fully fund multiple phase II trials
- ✓ **Comprehensive review of Xanamem dataset and scientific literature,** to optimise clinical trial designs and seeking a minimum effective dose

Next steps

Actinogen well placed to commence optimised Phase II clinical trials in the near-term

- ❑ Dose ranging study bridging mild cognitive impairment (MCI) due to Alzheimer's disease (AD) trial
- ❑ Fragile X syndrome (FXS) trial

Actinogen Medical

1. In Phase1 XanaHES trial in healthy elderly volunteers
2. U.S. Food and Drug Administration (FDA)

Clinical development pathway

Major clinical trials to be initiated in CY21 targeting brain penetration, improved cognition and other benefits

Planned studies	Pathway (illustrative)	*Outlook*
Mild cognitive impairment due to **Alzheimer's disease**	**XanaMIA** **Part A:** 10mg, 5mg, Placebo **Part B:** MCI due to AD	*Future trials informed by XanaMIA data (with partnership potential)*
Anxiety, sleep & behavioural problems in **Fragile X syndrome**	FDA Pre-IND Meeting → **XanaFX** Phase II trial	*Positive outcomes expected to lead to a pivotal Phase III trial*
Additional indication	Review and finalise selection of additional target → **Target indication** Phase II trial	

Actinogen Medical

Mild cognitive impairment
due to
Alzheimer‘s disease



Bridging positive Phase I cognition data to Alzheimer's patients

XanaMIA Study | **XanaMIA - Part A** → **XanaMIA - Part B**



>US$13.7B

Target annual peak sales[1]

Actinogen Medical

Source: Alzheimer's Association, aibl study; Bio-Link Analysis

1. Sales in 2036. Case assumes: (1) Launch: US 2027, EU5, JP and ROW 2028; (2) Penetration: 30% of mild AD and MCI markets in 5 years, sustained for 6 years with patent extension; (3) Pricing: US – US$24/day gross (US$19/day net), ROW: 50% of US price.

Breakthrough results achieved

Phase 1 XanaHES study demonstrated statistically significant cognitive efficacy signal in multiple cognition domains based on Cogstate Cognitive Test Battery as early as 2 weeks[1]

Working memory (One Back Test)

Strongly statistically significant result

Visual attention (Identification Test)

Statistically significant result



Psychomotor function (Detection Test)

Good trend to a positive result



Treatment Group
Xanamem 30pts — Placebo 12 pts

Efficacy results achieved through sensitive and modern testing method which can now be utilised in future studies supported by increasing clinical adoption

Actinogen Medical

Notes: All values are the means of observed data. p values were calculated with an ANCOVA (analysis of covariance) model using Baseline values as a covariate.
1. XanaHES Phase 1 clinical trial treated healthy elderly patients with 20mg Xanamem daily (n=30 active, n=12 placebo)

Review of data supports a low Xanamem dose

Human Target Occupancy Study PET data demonstrates consistent suppression of enzyme activity at 5mg Xanamem doses and above



PET data demonstrates that Xanamem extensively binds to the 11β-HSD1 enzyme throughout the brain, with high post-treatment effects (absence of colour) after 7 days at all doses, even a 5mg Xanamem dose.

This is consistent with full hormonal pharmacodynamic activity seen with 10mg Xanamem in clinical trials.

Actinogen is seeking to confirm the minimum effective dose of Xanamem to use going forward.

Actinogen Medical

Note: Study population consisted of ~50% healthy subjects (cognitively normal) and ~50% with Alzheimer's disease. Subjects dosed for seven days.
Baseline: Mean of baseline scans of patients in that dose group; After dose: Mean of post-dosing (7 days) scans in that dose group.

XanaMIA Phase II trial to commence mid CY21

Targeting the first stage of Alzheimer's disease

XanaMIA - Part A

- **Healthy older subjects -** with normal cognition, ≥50 years of age (same as XanaHES trial)
- **Endpoints and testing criteria -** to leverage modern and highly sensitive cognition tests (Cogstate, iDSST)
- **Dose ranging -** at 5mg, 10mg Xanamem once daily

Dose ranging study to healthy elderly to **confirm minimum effective dose of Xanamem**

XanaMIA - Part B

- Targeting subjects with **mild cognitive impairment** due to Alzheimer's disease (using positive serum biomarkers)
- Bridging to patients with **modern and sensitive cognition tests** (Cogstate, iDSST) from Part A
- Introducing other cognitive and functional endpoints that are **accepted by regulators for later studies**: final selection after reanalysis of XanADu trial Alzheimer's data

Phase II trial to **assess efficacy of Xanamem** in patients with MCI due to AD

Actinogen Medical

XanaMIA is designed to maximise success

Learnings from the XanaHES and XanADu trials have enabled us to pursue an optimised testing platform

Modern testing capabilities (Cogstate Neurological Test Battery)

- ✓ Highly sensitive computerised test battery measuring memory, attention, and brain processing speed
- ✓ Easily and reproducibly administered on iPad, with clearly defined endpoints
- ✓ Positive data with Xanamem in prior trial and used in other Phase II cognition trials
- ✓ FDA approved[1] digit symbol substitution test (iDSST) included in Cogstate platform - an extra measure of processing speed

Defined patient selection criteria for MCI population

- ✓ Positive serum biomarkers to confirm MCI is related to Alzheimer's disease in each patient
- ✓ Early stage of disease, to ensure each patient does not have functional impairment present in later stages of Alzheimer's disease

Actinogen Medical

1. Approved by FDA for vortioxetine anti-depressant label cognitive claim

Fragile X syndrome

Fragile X is the most common cause of developmental problems including autism and mental retardation

Fragile X syndrome is an attractive opportunity

Fragile X syndrome (FXS) is a rare genetic condition caused by a mutation to the FMR1 gene located on the X chromosome

Unmet medical need	▪ Management of FXS is often complex, with life-long treatment required for patients ▪ **There are no approved drugs to treat FXS**
Strategic benefits	▪ Xanamem in FXS has been awarded **Rare Paediatric Disease Designation**, and is expected to be eligible for Orphan Drug Designation ▪ Provides attractive regulatory, development, and commercial benefits
Data generation	▪ Data generated could be leveraged for other indications ▪ **Presents a significant potential upside with FXS-related conditions**, such as Autism Spectrum Disorder
Valuable commercial opportunity[1]	▪ Estimated **global market size of ~US$250M** ▪ FXS occurs in approx. 1 in 2500-4000 males and 1 in 7000-8000 females (averages to 1 / 4500)

Actinogen Medical

FMR1: Fragile X mental retardation 1

1. FSX market in 2026. GlobalData analyst report 2018. Projection for 7 major markets: US, France, Germany, Italy, Spain, UK, Japan

Strong scientific rationale for Xanamem as a treatment in FXS

Pre-clinical mouse model of Fragile X indicates possible efficacy[1]



Symptoms of Fragile X syndrome are all potentially amenable to Xanamem therapy

XanaFX trial target symptoms:

Anxiety[2]

Sleep problems

Behaviour problems/ hyper-reactivity

Other FXS symptoms potentially amendable to Xanamem therapy:

Cognitive impairment

Learning disabilities

Speech and language deficits

Preclinical studies support cortisol inhibition as a potential treatment of anxiety and other symptoms in FXS patients

Anxiety, sleep and behavioural problems in FXS are often associated with raised cortisol; Xanamem MoA (11ß-HSD1 of cortisol) has potential to improve symptoms

Actinogen Medical

1. Pre-clinical FMR1 knock-out mouse model using BVT 2733 as the 11β-HSD1 inhibitor showed highly significant results (***p<0.0001). Normal mouse is a wild-type mouse. (Source: Vanderklish PW. 2019. Compounds for treatment of emotional/psychological symptoms in fragile x syndrome, WO 2019/075394 Al.)
2. ~90% of FXS patients suffer symptoms of anxiety

Recent developments underpinning the Fragile X Phase II trial

FDA designations

- ✓ **Rare Paediatric Disease Designation** (RPDD) received in Feb 2021
- ✓ Priority (6-month) review for Xanamem FX
- ✓ Transferable (including by sale) Priority Review Voucher - if Xanamem is first registered in the US for FXS
- ✓ Orphan Drug Designation potential

Provisional XanaFX design

- Planning for ~30 adolescent males (12-18 years old) with FXS
- Double-blind placebo-controlled trial
- Evaluating safety and efficacy of Xanamem on dimensions of anxiety, sleep, attention and behavioural problems

Key upcoming milestones

Pre-IND feedback mid CY21

XanaFX trial to **commence H2 CY21**

Top line data expected end CY22

Actinogen Medical

Note: Trial design and timing is dependent on a number of external factors (including regulatory approvals)

Outlook

Significant value upside for Actinogen

Accelerate clinical development

- Expand pipeline with additional indications and clinical trials, providing multiple shots on goal
- Generate data to optimise potential partnership discussions
- Scale up and optimise manufacturing to prepare for commercially viable, large scale production

Potential commercial & corporate value

Big Pharma engagement

- Actinogen actively engaging with potential future partners on a regular basis
- High level of commercial interest and deal flow
- Recent AD deal value of ~US$1B (US$160M - US$2.4B range)[1]

RPDD

Transferable PRV voucher

- Eligible through RPDD recently granted by FDA[2]
- Recently traded for US$100M-US$125M[3]

High company valuations

- Companies with a lead asset in phase II or III development for AD have valuations between ~US$350M-$1.4B[4]

1. US$1B based on the average disclosed values of 13 major global pharmaceutical deals (Oct 2018 to Mar 2020) considered to have material interest in AD (Source: Bio-Link analysis)
2. Eligible for a transferable (including by sale) Priority Review Voucher under Rare Paediatric Disease Designation from the FDA (if Xanamem is first registered in the US for FXS)
3. Potential to receive a Priority Review Voucher (PRV) upon approval in FXS – (Source: PRV value adapted from FDA website; Company press releases; priorityreviewvoucher.org)
4. Vivoryon Therapeutics, phase IIb AD lead asset (EURONEXT Amsterdam: 292 euro / ~US$350m); Athira Pharma, phase II AD lead asset (NASDAQ GS:US$610m); Cortexyme, phase III AD lead asset (NASDAQ GS:US$1.1B) and same drug in phase II for periodontal disease and Parkinson's disease; Cassava Sciences, AD lead asset phase III-ready (NASDAQ GS:US$1.41B). All companies' value primarily attributed to their lead AD asset. Market capitalisations as of 16/4/2021.

Actinogen Medical

Next steps and key catalysts

Actinogen has a strong balance sheet to execute its strategy and progress Xanamem clinical development

- ❑ **Clinical trials to commence in 2021***
  - ➢ XanaMIA Part A data expected in H1 2022
  - ➢ XanaFX data expected by early 2023
  - ➢ XanaMIA Part B data expected 2023
- ❑ **Pursue other high priority indications**
  - ➢ Leverage strong academic, grant collaborations
- ❑ **Expand team to pursue aggressive timelines**
- ❑ **Publications and scientific presentations**

Actinogen Medical

*Note: Timing dependent on a number of external factors, including regulatory approvals.

Appendix

Corporate overview

Trading Information

52 week high	A$0.062
52 week low	A$0.018
Number of shares	1,660.6M
Market capitalisation (20 April 2021)	A$99.6M
Net cash[1]	A$15.2M

Major Shareholders

BVF Partners	14.4%
Steven Gourlay[3]	3.8%
Edinburgh Technology Fund	2.9%



Share Price Performance[2] (YTD)



Source: IRESS
1. Cash as at 31 March 2021
2. Volume traded on 5 Feb 2021 of 283.1M has been capped due to differences in volume.
3. Holding based on loan plan shares (~48M), and shares acquired in the 2021 shortfall placement (~15M)

Strong Leadership and Management

Leadership has a strong track record in drug development and extensive commercial experience

Experienced Board of Directors..

Dr. Geoff Brooke

Chairman

MBBS; MBA

- **30+ years experience** in the healthcare investment industry
- Founder and MD of Medvest Inc and GBS Venture Partners

Dr. George Morstyn

Non-Executive Director

MBBS; PhD; FRACP; MAICD

- **25+ years experience** in biotech investment and drug development
- Board member of Cancer Therapeutics and Symbio; Former Senior VP and CMO at Amgen

Mr. Malcolm McComas

Non-Executive Director

BEc, LLB; FAICD; SF Fin

- **25+ years experience** in the financial services industry
- Chairman of Pharmaxis and Fitzroy River Corporation; formerly senior leadership roles in investment banking

...with a talented management team in place

Dr. Steven Gourlay

CEO & MD

MBBS; PhD; MBA

- **30+ years experience** in the development of novel therapeutics and has significant regulatory experience interacting with FDA and EMA
- Formerly the founding Chief Medical Officer at US-based Principia Biopharma Inc., and Senior Director of Genentech

Jeff Carter

Chief Financial Officer

B. Fin Admin;
M. App. Fin; CA

Tamara Miller

Vice President Drug Development & Strategy

M.Med; M.PharmSci;
BSc; MSc; PMP; CPPM

Miriam Roesner

Clinical development manager

BASc

See full team and bios at: https://actinogen.com.au/our-company/#about-us

Actinogen Medical

Esteemed Advisory Boards

World-leading, premier academics involved in the development of Xanamem

Xanamem Clinical Advisory Board

Positions Xanamem at the forefront of drug development

Prof. Craig Ritchie
Chair

- World-leading authority on dementia; senior investigator on 30+ drug trials
- Chair of the Scottish Dementia Research Consortium; Professor of the Psychiatry of Ageing' Director of the Centre for Dementia Prevention (University of Edinburgh)

THE UNIVERSITY of EDINBURGH

Prof. Colin Masters
AO

- **35+ years research** on Alzheimer's disease and other neurodegenerative diseases
- Laureate Professor of Dementia Research and Head, Neurodegeneration Division at The Florey Institute (UniMelb)

THE FLOREY INSTITUTE OF NEUROSCIENCE & MENTAL HEALTH
THE UNIVERSITY OF MELBOURNE
The Royal Melbourne Hospital

Prof. Jeffrey Cummings

- World-renowned Alzheimer's researcher and leader of clinical trials
- MD, ScD; Founding Director of the Cleveland Clinic Lou Ruvo Center for Brain Health
- Recognised for this work through various awards

Cleveland Clinic

Scientific Advisory Board

Combining deep understanding of endocrinology, 11β-HSD1 and drug discovery

Prof. Alan Boyd

- **30+ years experience** in the pharmaceutical industry, with senior management roles
- Experience supporting early-stage life-science companies through Boyd Consultants
- Faculty of Pharmaceutical Medicine President, Royal College of Physicians, UK

BOYDS

Prof. Jonathan Seckl

- **Undertaken extensive research** in endocrinology
- Senior VP at the university of Edinburgh; Chaired Panels for MRC, Innovate UK and Wellcome Trust
- MBBS UCL, PhD (London)

THE UNIVERSITY of EDINBURGH

Prof. Brian Walker

- **20+ years research** in the area of disease
- Extensive experience advising for pharmaceutical R&D
- Pro Vice Chancellor for Research Strategy & Resources at Newcastle University, UK

Newcastle University

Prof. Scott Webster

- Chair of Medicines at the Centre of Cardiovascular Science, University of Edinburgh
- Former positions across both biotech and academia
- Founder and Chief Scientific Officer at Kynos Therapeutics

THE UNIVERSITY of EDINBURGH

Actinogen Medical

Disclaimer

This presentation has been prepared by Actinogen Medical Limited. ("Actinogen" or the "Company") based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Actinogen, nor does it constitute financial product advice or take into account any individual's investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Actinogen and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Actinogen is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Actinogen securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Actinogen its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

The information presented in this presentation is subject to change without notice and Actinogen does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation.

This presentation is not for general distribution or third party reliance or use.

This presentation contains certain budget information, forecasts and forward looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management in respect of which there is **NO guarantee of future performance**. Such budget information, forecasts and forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Actinogen to be materially different from the results or performance expressed or implied by such forward looking statements. These risks and uncertainties include, but are not limited to the performance of Actinogen in its clinical trials including whether it's technology proves to be a safe and effective treatment, market penetration, competition from any other similar products, intellectual property risks (including securing rights in technology and patents) and global economic conditions. Furthermore, Actinogen's research, product development, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. There is no guarantee that Actinogen will obtain the required approvals, licences and registrations from the relevant authorities in jurisdictions in which it operates. Actinogen or others could identify product and efficacy issues relating to the safety of our technology. Accordingly, all forward looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the political and economic environment in which Actinogen will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. There is no guarantee that Actinogen will achieve its stated objectives/milestones, that any of its forecasts will be met or that forward looking statements will be realised. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Neither Actinogen nor any other entity or person in or associated with Actinogen guarantee any return (whether capital or income) or generally the performance of Actinogen or the price at which its securities may trade. Any investment in Actinogen is subject to investment risks including the possibility of loss of capital invested and no return of income or payment of any dividends.

To the maximum extent permitted at law, Actinogen and all of its representatives, directors, officers, partners, employees or professional advisers (**Parties**) exclude all direct and indirect liability arising out of or in connection with any use or reliance of the information contained or described within this presentation. Other than to the extent required by law (and only to that extent), the Parties do not make any representation or give any assurance, guarantee or warranty (express or implied) as to, nor assume any responsibility or liability for, the authenticity, origin, validity, accuracy, suitability or completeness of, or any errors in or omissions from, any information, statement or opinion contained in this presentation or any accompanying, previous or subsequent material or presentation.